Company Quick10K Filing
Semler Scientific
10-Q 2020-03-31 Filed 2020-05-07
10-K 2019-12-31 Filed 2020-03-09
10-Q 2019-09-30 Filed 2019-11-06
10-Q 2019-06-30 Filed 2019-08-02
10-Q 2019-03-31 Filed 2019-05-03
10-K 2018-12-31 Filed 2019-03-07
10-Q 2018-09-30 Filed 2018-11-01
10-Q 2018-06-30 Filed 2018-08-03
10-Q 2018-03-31 Filed 2018-05-03
10-K 2017-12-31 Filed 2018-03-08
10-Q 2017-09-30 Filed 2017-11-03
10-Q 2017-06-30 Filed 2017-08-11
10-Q 2017-03-31 Filed 2017-05-12
10-K 2016-12-31 Filed 2017-03-17
10-Q 2016-09-30 Filed 2016-11-03
10-Q 2016-06-30 Filed 2016-08-02
10-Q 2016-03-31 Filed 2016-05-05
10-K 2015-12-31 Filed 2016-02-26
10-Q 2015-09-30 Filed 2015-11-03
10-Q 2015-06-30 Filed 2015-08-04
10-K 2014-12-31 Filed 2015-02-13
10-Q 2014-09-30 Filed 2014-11-03
10-Q 2014-06-30 Filed 2014-08-01
10-Q 2014-03-31 Filed 2014-05-01
10-Q 2013-03-31 Filed 2015-05-04
8-K 2020-05-04 Earnings, Exhibits
8-K 2020-03-03 Earnings, Exhibits
8-K 2019-11-06 Enter Agreement, Leave Agreement, Exhibits
8-K 2019-10-30 Earnings, Exhibits
8-K 2019-10-02 Shareholder Vote
8-K 2019-07-26 Earnings, Exhibits
8-K 2019-05-03 Enter Agreement, Leave Agreement, Exhibits
8-K 2019-04-29 Earnings, Exhibits
8-K 2019-02-27 Earnings, Exhibits
8-K 2018-10-26 Earnings, Exhibits
8-K 2018-10-04 Officers, Exhibits
8-K 2018-10-02 Shareholder Vote
8-K 2018-07-31 Earnings, Exhibits
8-K 2018-05-01 Earnings, Exhibits
8-K 2018-02-28 Earnings, Exhibits

Semler Scientific Financials

SMLR Metrics, Comps, Filings

Quarterly | Annual

Business

We are an emerging growth company providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Our mission is to develop, manufacture and market innovative proprietary products and services that assist our customers in evaluating and treating chronic diseases. In 2011, we began commercializing our first patented and U.S. Food and Drug Administration, or FDA, cleared product, which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease, or PAD. In March 2015, we received FDA 510(k) clearance for the next generation version of our product, QuantaFlo™, which we began commercializing in August 2015. We believe our products and services position us to provide valuable information to our customer base, which in turn permits them to better guide patient care.

In the year ended December 31, 2018, we had total revenues of  $21,491,000 and net income of $5,014,000 compared to total revenues of  $12,452,000 and a net loss of  $1,510,000, in 2017.

We currently market only one patented and FDA-cleared vascular-testing product, QuantaFlo™, to our customers, who include insurance plans, physician groups and risk assessment groups.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Alfacourse (ALFA) 407,519 -40,331.9 -303% 5 19 0 0 -14 -10 407,514
ETFS Silver Trust (SIVR) 406,944 10.5 10% 394,201 97 0 0 38,813 38,813 406,944
Farmers Capital Bank (FFKT) 402,755 8.9 0% 10,900,000 1,434,070 0 0 15,694 34,787 309,509
Keryx Biopharmaceuticals (KERX) 402,246 0% -4.1 -60% 151,784 206,003 94,218 0 -90,838 -90,648 376,100
TCR2 Therapeutics (TCRR) 399,387 -10.2 -19% 179,511 8,357 0 0 -34,772 -34,214 349,653
Hennessy Capital Acquisition III (HCAC) 381,265 0% -35.1 -18% 421,802 475,144 431,588 0 -74,570 -21,261 746,662
Charter Financial (CHFN) 381,167 7.4 1% 1,625,835 1,401,429 0 0 16,852 35,949 265,269
Invesco DB Agriculture Fund (DBA) 380,908 -13.2 -7% 384,159 253 0 0 -28,794 -28,769 380,908
Karuna Therapeutics (KRTX) 379,989 -9.0 -15% 164,227 1,697 0 0 -24,178 -24,163 218,389
Semler Scientific (SMLR) 365,490 88% 43.9 65% 18,857 4,755 23,616 20,861 12,252 8,128 356,948
Gulfmark Offshore (GLF) 354,229 0% 26.1 -6% 417,402 135,430 78,633 0 -27,052 15,946 416,697
PHH (PHH) 354,128 0% -0.2 -10% 1,442,000 953,000 315,000 0 -138,000 -149,000 37,128
Harpoon Therapeutics (HARP) 349,762 0% -5.8 -29% 142,388 35,157 4,606 0 -41,304 -39,604 228,562
Government Properties Income Trust (GOV) 349,491 0% 1.1 -1% 4,360,249 2,693,636 343,443 0 -34,694 297,616 316,458
JEM Capital (JEM) 345,932 -17,698.3 0 115 0 0 -20 -20 345,931
Fellazo (FLLZ) 345,056 -1,969.0 -849% 21 680 0 0 -175 -175 345,056
Castle Biosciences (CSTL) 334,822 85% 35.2 4% 113,200 30,864 25,513 21,812 4,580 7,539 265,251
New York & Company (NWY) 330,180 29% -12.5 -4% 486,431 430,014 850,241 249,177 -21,388 -21,254 264,615
Invesco DB US Dollar Index Bullish Fund (UUP) 329,522 16.0 6% 330,667 203 0 0 20,586 20,596 329,522
Zynex (ZYXI) 324,063 62% 25.1 37% 24,724 8,332 40,647 25,317 9,167 12,416 312,129

Balance Sheet ($'000)2013-03-312014-03-312014-06-302014-09-302014-12-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash3,0617,6126,5545,9734,1562,3401,9254051,4411,0225176221594965781,4574192,0093,0873,2844,5444,1828,542
Accounts Receivable3561571273113552624391,2785996078978771,1818851,4771,3152,3771,8502,4802,8012,5333,5093,271
Inventory
PP&E26576948188542548557681760763772783322356427448457488520563
Assets6,4038,7417,6577,2277,5005,6783,5203,0793,4253,0612,9603,0723,1163,1553,8714,2384,2575,3127,0437,7199,0559,82418,857
Accounts Payable891391612178911661839390430281450310546647488341185251280257405669
Long-Term Debt1,0035441,8061,8631,66816600
Liabilities3,8081,8011,7492,6074,0643,9802,9894,1515,0865,5925,7665,9916,3546,7907,4596,8215,7815,0964,7313,5232,8943,6034,755
Stockholders' Equity2,5956,9405,9084,6203,4361,698531-1,072-1,661-2,531-2,806-2,919-3,238-3,635-3,588-2,583-1,5242162,3124,1966,1616,22114,102
Income Statement ($'000)2013-03-312014-03-312014-06-302014-09-302014-12-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue1,2028378468971,0551,3031,5622,9341,5011,6361,9822,3162,0552,5783,6074,2134,4635,4845,5796,7617,9538,902
Cost of Revenue2201551721781882443851,960417533398525540592724698704680615896885974
Gross Profit9826826747198671,0591,1779741,0841,1031,5841,7911,5151,9862,8833,5153,7594,8044,9645,8657,0687,928
R&D
SG&A2,0211,2431,2671,8241,8361,9662,4614,7261,7461,7911,6561,6661,8262,0662,3752,6542,5792,7802,8313,4423,7824,200
Tax0977-4,671
Net Income-1,372-817-1,032-1,466-1,200-1,341-1,580-4,208-1,006-966-362-220-871-850-412537061,4531,4681,8542,6197,779
Cash Flow ($'000)2013-03-312014-03-312014-06-302014-09-302014-12-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-1,503-1,026-868-366-1,562-919-69-1,644-1,093-447-366102-505435251440-3661,1431,7032,6804,710
Cash Investing-90-120-164-112-2,145-2161,727-425-71-250-234-259-402-201-183-182-92-210-456-386-366
Cash Financing4988,024-26-1031,890414-2,0735492,2002789526244410314621-58014513-2,65616